ONA, OTCQBNANF) CEO David Regan talked with Proactive about the company's recent ethics committee approval for a pilot cancer study. This approval represents the next step in Sona Nanotech's clinical development pathway, building on its current early feasibility study focused on late-stage melanoma patients. 